The Prevention of WEight Regain in diabetes type 2 (POWER) study: the effectiveness of adding a combined psychological intervention to a very low calorie diet, design and pilot data of a randomized controlled trial by Berk, K.A.C. (Kirsten) et al.
The Prevention Of WEight Regain in diabetes type 2 
(POWER) study: the effectiveness of adding a 
combined psychological intervention to a very low 
calorie diet, design and pilot data of a randomized 
controlled trial 
Kirsten AC Berk1,2 
Email: k.berk@erasmusmc.nl 
Hanneke Buijks2 
Email: h.buijks@erasmusmc.nl 
Behiye Ozcan1 
Email: b.ozcan@erasmusmc.nl 
Adriaan van’t Spijker2 
Email: a.vantspijker@erasmusmc.nl 
Jan JV Busschbach2 
Email: j.vanbusschbach@erasmusmc.nl 
Eric JG Sijbrands1* 
*
 Corresponding author 
Email: e.sijbrands@erasmusmc.nl 
1
 Department of Internal Medicine, division of Pharmacology, Vascular and 
Metabolic diseases, Erasmus Medical Centre, Rotterdam, the Netherlands 
2
 Department of Medical Psychology and Psychotherapy, Erasmus Medical 
Centre, Rotterdam, the Netherlands 
Abstract 
Background 
Obesity is of major pathogenetic importance to type 2 diabetes, it contributes to poor 
glycemic control and increases the risk of cardiovascular disease. Over 80% of patients with 
diabetes type 2 are overweight. To achieve a more favourable risk profile, changes in diet and 
lifestyle are needed. However, current treatment programs for obese DM type 2 patients are 
not effective in the long term. In this RCT, we compare the effectiveness of a Combined 
Psychological Intervention (CPI) and usual care in maintaining the favourable effects on 
weight and risk profile during 2 years of follow-up after a Very Low Calorie Diet (VLCD). 
Methods and design 
In a randomised parallel group intervention study, 140 patients with type 2 diabetes and 
overweight (BMI>27 kg/m2) will be recruited from the outpatient department of the Erasmus 
Medical Centre. 
After obtaining ≥5% of weight loss with a VLCD, participants will be randomly assigned to 
CPI or usual care for 10 weeks. CPI consists of cognitive behaviour therapy, problem solving 
therapy and proactive coping. 
Primary outcome measure is weight change (kg). 
Other outcome measures are Body Mass Index (BMI = weight (kg)/length (m)2), waist 
circumference (cm), systolic blood pressure (mmHg), HbA1c (mmol/mol), lipid levels (LDL, 
HDL, TG (mmol/l) and chol/HDL-ratio), antidiabetic agents and doses, cardiovascular risk 
profile (UKPDS), lifestyle and quality of life (EuroQol EQ-5D). Psychosocial parameters are 
also studied, as secondary outcomes as well as determinants for weight loss. 
When successful, we want to conduct an analysis of the cost effectiveness of the intervention 
as compared to usual care. 
Discussion 
We expect that a CPI after a VLCD will be effective in maintaining weight loss and 
improving cardiovascular risk and glycaemic control, while being cost-effective and 
improving quality of life in patients with type 2 diabetes. 
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Background 
Diabetes has become a worldwide epidemic: the estimated global prevalence was 2,8% in 
2000 and is expected to rise up to 4,4% in 2030. In the year 2000 the excess global mortality 
attributable to diabetes was 5,2% making diabetes the fifth leading cause of death.[1] The 
increase in prevalence is associated with aging of the population, the increasing prevalence of 
obesity in combination with physical inactivity. Cardiovascular disease is the major cause of 
death among patients with diabetes. An intensive pharmaceutical and behavioral therapy 
treatment has been estimated to reduce the risk of cardiovascular and micro vascular events 
by approximately 50%.[2] 
Approximately 80% of the people with type 2 diabetes are overweight. Losing weight is the 
cornerstone of prevention and treatment of type 2 diabetes: it decreases the resistance to 
insulin, improves glycaemic control and reduces hypertension and lipid abnormalities.[3-5] 
Weight loss interventions thus may contribute to a reduction of cardiovascular risk and is 
shown to reduce mortality in patients with type 2 diabetes and obesity.[6] 
Unfortunately, interventions aimed at weight reduction have only a limited effect in the long 
run because of regain of the initial weight loss. The required long-term lifestyle change seems 
difficult to achieve.[7] A meta-analysis of weight loss interventions in adults with type 2 
diabetes showed that multi-component interventions including Very Low Calorie Diets may 
hold promise for achieving weight loss.[7,8] However, trials with long follow-up periods are 
lacking and the most effective type of psychological intervention remains unclear. 
In the present study, we determine the effect of an integrated multi-model cognitive group 
therapy, in obtaining and maintaining favourable effects on weight and cardiovascular risk 
profile during 2 years of follow-up after a Very Low Calorie Diet. 
Very Low calorie diet 
A Very Low Calorie Diet (VLCD) is a diet of less than 800 kilocalories (kcal) daily. [4] The 
very low intake of fat and carbohydrates, but normal amount of proteins (0,8 g/kg ideal 
bodyweight per day) enhances lipolysis and ketosis while preventing a negative nitrogen 
balance, sparing lean body mass.[9] 
The most commonly used VLCD’s are commercially available mixed-formula diets, 
containing various amounts of carbohydrate, fat and high quality protein, and have proven 
safety for use in patients with type 2 diabetes.[9,10] 
The short-term effects (i.e. < 6 months) of a VLCD in overweight patients with type 2 
diabetes are favourable on weight, glycaemic control, hypertension and dyslipidaemia.[11-
15] However, study outcomes are less positive in the long term (i.e. > 1 year follow-up): 
patients regain most of the lost weight and HbA1c returns to the same value as prior to the 
intervention. Nonetheless, participants often needed less anti-diabetic agents.[16-18] The 
study of Jazet, et al.[19] seems to be a positive exception: 18 months after a 30-day VLCD 
period, favourable effects on weight, blood pressure and dyslipidaemia were maintained in 18 
obese patients with diabetes type 2, but with no effect on HbA1c. The authors indicated that 
the success was based on the strong motivation of the patients to prevent a need for insulin 
and a slow reintroduction of normal diet. Limitations of this study, however, were the small 
intervention group and the lack of a control group. 
Taken together, randomized controlled trials of sufficient duration focused on prevention of 
weight gain after a VLCD in DM type 2 patients are required to improve the effectiveness of 
VLCDs. 
Weight maintenance 
To achieve weight maintenance after successful weight loss, a permanent behaviour change is 
needed. For this purpose, a variety of psychological interventions have been implemented in 
weight reduction programmes. Behaviour therapy and cognitive behaviour therapy (CBT) are 
potential psychological interventions facilitating better maintenance of weight loss.[20] CBT 
is used to describe a wide range of techniques to change thinking patterns and behaviours. As 
a result, interventions are heterogeneous and the findings are difficult to compare. 
We identified three promising psychological interventions to attain better results in sustaining 
weight loss: cognitive (behaviour) therapy, problem solving therapy and proactive coping. In 
the current study, we propose to combine them into an integrated weight maintenance 
programme. 
Cognitive behaviour therapy 
Within cognitive psychology, humans are regarded as information processing systems, where 
knowledge is organized in so-called schemas. Cognitive schemas are activated by incoming 
information, leading to cognitions (thoughts), emotions and subsequently to behaviour. 
According to the founding father of the cognitive therapy, Aaron Beck, emotional disorders 
such as depression and anxiety disorders result from dysfunctional schemas. Cognitive 
therapy focuses on changing dysfunctional schemas and cognitions, using behavioral 
experiments and challenges.[21] In eating disorders, the cognitive model was first used to 
treat bulimia nervosa by adjusting overvaluation of weight and shape based on low self-
esteem.[22,23] In the treatment of obesity, this model is combined with the cognitive model 
for addiction, which is based on the assumption that addictive behaviour is enhanced by 
dysfunctional cognitions during exposure to external stimuli like the smell or sight of 
food.[24] 
In a Cochrane review[20] concerning the effect of psychological interventions in the 
treatment of overweight and obese patients, positive effects of cognitive behaviour treatment 
on weight loss were described, particularly when combined with diet and/or physical activity. 
In a number of studies, weight loss was enhanced significantly by the addition of the 
cognitive component to an intervention of diet and/or exercise.[25-28] Moreover, it was 
found that a longer duration of the intervention and more frequent clinical contact was 
associated with an increased effect. However, studies with substantial follow-up (i.e. > 1 
year) are lacking. 
In patients with type 2 diabetes, psychotherapy (especially CBT) improves glycaemic control 
(HbA1c −1,0%) and psychological well-being.[29] Surprisingly, CBT did not appear to affect 
weight control in this patient group. Perhaps this was caused by too short duration of the 
studies (i.e. <6 months), as CBT may encourage long-term behavioral changes.[29] 
Problem solving therapy 
Problem Solving Therapy (PST) is defined as the self-directed cognitive-behavioral process 
by which a person attempts to identify effective or adaptive solutions for specific problems 
encountered in everyday living.[30,31] PST is recognized as an effective treatment of 
depression.[32,33] The problem-solving model for obesity treatment was first described by 
Perri, Nezu and Viegener in 1992 [34] and proposes that active problem solving efforts by a 
health care provider can help the obese person encounter everyday problems in their weight 
management. Perri, et al. found significantly greater long-term weight reductions in 
participants, who completed a PST-intervention, compared to participants receiving 
behavioral therapy.[35] Moreover, a recent study showed that people with better problem-
solving skills lost more weight and were more compliant to therapy.[36] 
Proactive coping 
Proactive coping (PC), directed at an upcoming instead of an ongoing stressor, is a new focus 
in positive psychology research. PC consists of efforts undertaken in advance of a potentially 
stressful event to prevent it or modify its form before it occurs. The theory described by 
Aspinwall and Taylor consists of five stages: PC starts with the ‘accumulation of resources’ 
such as time, money, planning or organizational skills and social support, so that one is 
prepared as much as possible to deal with future threats. ‘Recognition’ refers to the ability to 
see a potential stressful event coming, followed by ‘initial appraisal’ (what is this and should 
I be worried about this?). The next stage consists of ‘initial coping efforts’: activities 
undertaken to prevent or minimize a recognized or suspected stressor. Finally, the ‘use of 
feedback’ involves the evaluation of the stressful event itself and the effects of one’s 
preliminary efforts.[37] 
Schwarzer and Taubert described PC as a way of aspiring a positive future by accumulating 
resources and realistic goal setting.[38] A recent publication has shown that the pursuit of 
goals was related to improved wellbeing, while preventing a negative future was not.[39] 
A study of the effects of PC on the self-care behaviours of newly diagnosed DM patients 
revealed that the treatment was highly appreciated and even after 9 months improvements in 
eating and exercising habits were seen. In addition, the intervention was effective in reducing 
both weight and blood pressure after 9 months, but had no effect on HbA1c or lipid 
profile.[40] 
In the current randomized study, we compare the effect of a Combined Psychological 
Intervention (CPI) with usual care on weight maintenance after a Very Low Calorie Diet. 
Hence, we do not compare the effectiveness of Cognitive Behaviour Therapy with neither 
Problem Solving Therapy nor Proactive Coping, but combine these three therapies into an 
integrated multi-model program. 
Objectives 
The primary objective of this study is to determine if an integrated multi-model cognitive 
group therapy, is more effective in preventing weight regain after a Very Low Calorie Diet 
compared to usual care. 
The secondary objectives are to investigate whether an integrated multi-model cognitive 
group therapy following a VLCD has an effect on glycaemic control, cardiovascular risk 
profile, psychological variables and quality of life, and subsequently to determine which 
patient group benefits most of the intervention. 
The tertiary objective is to determine whether the intervention is cost-effective. 
Ethical approval 
This research is approved by the Medical Ethics Committee of the Erasmus Medical Centre 
in Rotterdam (reference number MEC-2009-143/NL26508.078.09), in compliance with the 
Helsinki Declaration. 
Methods/design 
Design of the study 
This study is a randomized controlled parallel group intervention trial. 
When patients lose equally or more than 5% of their bodyweight in the first 8 weeks of the 
VLCD, they are included in the intervention trial testing CPI. This arbitrary cut-off value was 
chosen because of its relatively large effect on the risk profile.[3] Moreover, we need a 
relevant weight loss to investigate weight maintenance after weight reduction. After 
randomization, stratified to the achieved weight loss at 8 weeks, participants are assigned to 
one of the following conditions: 
1. VLCD + conventional treatment 
2. VLCD + conventional treatment + CPI 
The duration of the diet period will be 20 weeks: 8 weeks of VLCD (<800 kcal/day) followed 
by 12 weeks of slowly reintroducing a normal, mildly energy-restricted diet (1300 kcal/day). 
During week 10 of the diet, the intervention group starts with a total of 17 sessions of CPI. 
The first 10 sessions are weekly sessions; followed by two 2-weekly sessions, two monthly 
sessions, two 3-monthly sessions and 1 session with an interval of 6 months. 
Outcome measurements are assessed at baseline, after finishing the intensive CPI-period at 4 
months and subsequently at 1 year, 1,5 years and 2 years after randomization. At 8 weeks 
(randomization after VLCD), only the primary outcome (weight) will be measured. 
Figure 1 shows the design of the study. 
Figure 1 Flow chart of participants. VLCD = Very Low Calorie Diet; CPI = Combined 
Psychological Intervention 
 
The study started in may 2010 with a pilot and inclusion will be completed in 2013. The 
follow-up will continue until 2015. 
Study population 
Patients are recruited from the outpatient diabetes clinic of the Erasmus Medical Centre in 
Rotterdam by the medical team, based on the in- and exclusion criteria shown in Table 1. In 
our hospital, a tertiary referral centre, we see both patients with only oral antidiabetic agents 
and patients treated with one or more insulin doses daily. In general, our patients will have 
more complex disease and more comorbidity compared to the average diabetic patient 
referred to a GP. How ever, GP’s can also directly refer their eligible patients to our trial. 
Patients interested in participating in the study will receive an information letter and a 
questionnaire to be filled in at home. Two weeks later they will visit the outpatient clinic for 
an intake interview with the researcher (KACB). Eligibility will be checked again. After 
signing the informed consent form by the patient, the baseline measurements will be 
performed. 
Table 1 eligibility 
Inclusion criteria: 
1 Diagnosed diabetes mellitus type 2 
2 Age 18–75 years 
3 BMI ≥ 27 kg/m2 
Exclusion criteria: 
6 Pregnancy or lactation during the study 
7 Inadequate expression of the Dutch language (spoken and written) 
8 Inability to lose ≥ 5% of bodyweight during the first 8 weeks of VLCD 
9 Severe psychiatric problems 
10 Significant cardiac arrhythmias, unstable angina, decompensated congestive heart failure, 
major organ system failure, untreated hypothyroidism and/or myocardial infarction, end-
stage renal disease, cerebrovascular accident or major surgery in the last 3 months. 
Patients with psychiatric disorders or major psychological disturbances are excluded from the 
trial. Patients with eating disorders (bulimia nervosa and binge eating disorder) or depression 
are not excluded, since it is expected that these conditions are common among patients with 
type 2 diabetes and previous research has shown that cognitive behaviour therapy can have 
beneficial effects in these patient groups.[28,41-43] We will analyze the effect of these 
background variables on the outcome of the intervention. 
Randomization 
Groups of 20 patients will start with a VLCD concomitantly. After 8 weeks of VLCD, the 
patients who lost ≥5% of bodyweight are randomly assigned to either or the intervention 
group (usual care + CPI) or the control group (usual care) with an allocation ratio of 1:1. The 
stratified randomization is computer controlled, carried out by a secretary and supervised by a 
statistician, who are both not involved in the trial. The reason for a stratified randomization is 
to avoid an unsuccessful randomization with regard to weight loss during the VLCD. It is not 
possible to correct afterwards in the analysis, as it is the primary outcome measurement. We 
defined the following strata (based on clinical experience): 
1. 5% - 7,5% 
2. 7,5% - 10% 
3. >10% weight loss after 8 weeks of VLCD. 
The statistician generates the allocation sequence and hands it over to the secretary of the 
department of Medical Psychology and Psychotherapy, who is not involved in the study, to 
guarantee allocation concealment. The secretary assigns the participants to their group and 
makes a list for KACB, who will plan their study appointments. 
Sample size calculation 
After randomization of 75 participants, the sample size calculation was carried out by an 
independent statistician to base it on realistic data. 
Sample size was calculated with SPSS 17.0, using the mixed-model ANOVA procedure 
described by Aberson.[44] 
Alpha was set at 0.05, power at 0.80 and the baseline-end correlation at 0.90. A clinically 
relevant difference between the treatment groups is 5% weight loss.[3] Mean weight at the 
start of the treatment is about 110 kg, with a standard deviation of 22, this equals an effect 
size of d = 0.25.[45] With this power calculation we estimate that we need 52 patients in each 
group. Anticipating a dropout rate of 25%, we aim for a total sample size of 140. 
For the most important secondary outcomes we calculated the detectable difference with the 
sample size of n=104, alpha 0.05 and power 0.80 (Table 2). The detectable differences are 
quite small, so the aimed sample size seems adequate to analyse at least these secondary 
outcomes. 
Table 2 Power calculation secondary outcomes 
Secondary outcome: SD: Detectable difference:(n = 104, β=0.8 α=0.05) 
Waist circumference 11 2.75 cm 
Blood pressure sys/dias 20/20 5/5 mmHg 
Total cholesterol 1.4 0.35 mmol/l 
LDL cholesterol 1.0 0.25 mmol/l 
HDL cholesterol 0.7 0.2 mmol/l 
Triglyceride 3.0 0.75 mmol/l 
HbA1c 12 3 mmol/mol 
Insulin 50 12.5 IU 
Depression (HADS score 0–21) 3 0.75 
Anxiety (HADS score 0–21) 4 1.0 
Self esteem (RSE score 10–40) 5 1.25 
Fatigue (CIS score 8–56) 13 3.25 
Concentration (CIS score 5–35) 8.5 2.1 
Motivation (CIS score 4–28) 6 1.5 
Activity (CIS score 3–21) 5 1.25 
Quality of life (EuroQol 5D score 1–3) 0.5 0.125 
Quality of life (EuroQol VAS 1–100) 21 5.25 
Blinding 
Given the nature of the intervention, it is impossible to blind the participants, CPI-therapist 
and researcher (KACB). Nevertheless, we will try to keep the intervention as separate as 
possible from the diabetes treatment, by giving participants strict instructions not to 
communicate about the intervention with their medical team. Patients are given the 
possibility to discuss problems related to the study with an independent medical doctor. The 
CPI group sessions will take place in another part of the hospital, outside the diabetes clinic, 
to ensure that patients and medical team will not run into each other. The VLCD is not a part 
of the intervention and can therefore be guided by the diabetes medical team. 
To avoid bias, measurements will be conducted by blinded medical assistants and analyses 
will be done by two analysts, independent of each other. 
The allocation sequence will be revealed to the researchers once recruitment, data collection 
and analyses are complete. 
Interventions 
Phase 0: very Low calorie diet 
The first part of the study (before randomization) is the same for all participants and consists 
of a Very Low Calorie Diet (VLCD) for the duration of 8 weeks, with a phase-out of 12 
weeks. When after 8 weeks of VLCD a loss of 5% or more of the initial bodyweight is 
reached, random allocation to the intervention- and control group will take place. Patients 
losing less then 5% of bodyweight in the first 8 weeks are excluded from the study and will 
receive usual care, including dietary advice. 
The use of a VLCD is an integrated part of the dietary treatment at our outpatient diabetes 
clinic. Normally, the patients are free to choose between the different types of weight 
reduction strategies. In the present study however, only one type of weight reduction therapy 
is used (VLCD). 
The product we use for this study is Glucerna SR®, a product specifically developed for 
patients with diabetes and based on a combination of slow released carbohydrates, a low-fat, 
high monounsaturated fatty acid content and the addition of dietary fibre. Various studies 
indicate that this product decreases the postprandial blood glucose levels, which may have a 
lowering effect on HbA1c. This diabetes-specific diet product is also used as a meal 
replacement for achieving weight reduction in people with type 2 diabetes, with positive 
effects on weight control, glycaemic control and lipid profile.[46-48]We have chosen to use a 
twice a day regimen of meal replacements, together with a small dinner, providing 750 kcal, 
67 g carbohydrates, 54 g protein and 32 g fat (of which 16 g monounsaturated fatty acids 
(MUFA)) a day and RDA recommendations in micronutrients. We believe that enabling the 
participants to have dinner with their family during the VLCD will improve compliance. 
We have developed a protocol for the use of a VLCD in patients with type 2 diabetes, where 
we describe the different aspects of the treatment. Oral anti-diabetic agents (except 
Metformin) and short-acting insulin analogues are discontinued, while the dosage of long-
acting insulin analogues and biphasic mixtures is halved, to avoid severe hypoglycaemia. 
GLP-1 or DPP-4 inhibitors will be continued. During the VLCD and gradual transition to a 
normal diet, medication is adjusted by means of glucose self-control and frequent contact 
with diabetes nurses and dieticians. The dose of any antihypertensive medication is also 
adjusted during VLCD and follow-up, in consultation with the responsible physician. 
Realimentation takes place by slowly reintroducing normal food in 12 weeks time, until 
participants use a lightly energy restricted diet (1300 kcal a day), according to national 
dietary guidelines. 
Phase 1: control group 
Following the VLCD-period and gradual reintroduction of normal diet, the control group 
receives usual care, provided by the diabetes team of the out-patient diabetes clinic of the 
Erasmus Medical Centre. Usual care consists of a 3-monthly visit to the physician and 
diabetes nurse, including medical examinations. Dietary treatment is part of usual care by 
referral to a specialized dietician. Patients are free to make additional appointments with their 
dietician in- or outside the hospital and they can choose to follow whatever diet they would 
like during the follow-up period. Both the number of visits to a dietician and the dieting 
methods, products and duration of the diet are noted during the follow-up period of 2 years. 
Dieticians in our hospital are all trained in motivational interviewing to motivate the patients 
in changing their lifestyle. All members of the diabetic team encourage the patients to get 
enough exercise, but we do not refer to an exercise programme. Patients in need of 
psychological help (ie psychological disorder, clinical depression, major eating disorder) are 
referred to a clinical psychologist in- or outside the hospital. In our population, these referrals 
are rare. Nonetheless, the number of visits to a psychologist as well as to other caregivers will 
be noted during this trial. CBT or techniques of PST and PC are no part of usual care. 
Phase 1: intervention group 
After 8 weeks of VLCD, the participants allocated to the intervention group start with CPI in 
groups of up to 10 patients, in addition to the basic treatment for diabetes and obesity, 
focusing on (self) regulation of blood glucose and the prevention/reduction of complications, 
according to national guidelines. The CPI sessions are guided by a trained 
psychologist/psychotherapist, with experience in diabetes care. Two psychologists (HB and 
AVTS) are involved in this study, so we can investigate the ‘therapist-effect’. 
The first 10 weekly sessions consist of cognitive behaviour therapy, partly based on the 
method developed by Werrij and colleagues from the University of Maastricht. [27] These 
CBT meetings are followed by 7 relapse prevention sessions. 
The aim of the first 10 sessions is to restructure dysfunctional cognitions on lifestyle, weight 
and body perception. 
Sessions 11–17 aim to prevent relapse by combining intervention techniques of CBT, PC and 
PST. Table 3 presents the treatment protocol in brief. 
Table 3 Brief presentation of the treatment protocol 
Weekly sessions  
Session 1 Introduction of the therapist and the group members 
 Agreements on attendance, commitment, homework and privacy 
 Setting realistic treatment goals 
 Explaining the rationale of the cognitive treatment 
 Introducing relevant concepts op CBT (situation, thoughts, emotions, 
behavior) and the use of the diary 
Sessions 2 – 4 Discussing rationale and the concepts of CBT 
 Explaining unrealistic and automatic thoughts 
 Identifying and challenging dysfunctional cognitions about eating, 
weight and shape (by Socratic dialogue) 
 Homework: cognitive diaries 
Sessions 5 – 8 Introducing the behavioral experiment 
 Challenging dysfunctional cognitions by setting up a behavioral 
experiment 
 Identifying and challenging ‘core beliefs’, the underlying self-schemas 
 Homework: cognitive diaries and behavioral experiments 
Sessions 9 – 10 Preparing for the oncoming ending of weekly sessions 
 Identifying and challenging dysfunctional cognitions about relapse 
 Introducing relapse prevention sessions 
Relapse prevention 
sessions 
 
Session 11 Challenging dysfunctional cognitions about relapse 
 Setting goals for the long term 
 Explaining Problem Solving Treatment and Proactive Coping 
Session 12 – 16 Implementing PST and PC in an individual plan 
Session 17 Preparing for treatment ending 
 Challenging dysfunctional cognitions about treatment ending 
 Personal reminder in difficult times 
After session 1, the structure of each session is as follows: 
– time for questions following the previous session 
– discussing home-assignments 
– explaining and practicing of cognitive (behavioral) techniques 
– discussing new home-assignments 
– summary and evaluation of the session (by completing the Session Rating Scale) 
In sessions 1–5 dysfunctional cognitions about eating, weight and shape are identified and 
challenged. Also exercise will be included in the sessions. Cognitive diaries are introduced 
and participants are encouraged to use these diaries at home to record personal critical 
situations and dysfunctional thoughts. They also score the credibility of their dysfunctional 
thoughts (0-100%). Furthermore, the validity of the dysfunctional thoughts is tested and 
alternative thoughts are generated. Guided by examples of the group, the group is acting as a 
research team, investigating the validity of dysfunctional cognitions and creating alternative 
and more realistic thoughts. The new thoughts are again scored on credibility (0-100%). 
Methods used for testing the validity of a person’s thoughts are the Socratic dialogue and 
behavioral experiments. Behavioral experiments are set up during the session, carried out at 
home, and discussed in the next session. 
The underlying schemas (‘core beliefs’) are explored during sessions 6–10. The validity of 
self schemas is tested in the same way as the other dysfunctional thoughts and recorded in the 
diary. 
Subsequently, 7 relapse prevention meetings are held to stabilize behaviour change, with 
increasing intervals until the end of the study (2 years). During these relapse prevention 
meetings, the acquired techniques will be repeated. In addition, techniques of Problem 
Solving Therapy are used to help participants coping with everyday problems they encounter 
while implementing their lifestyle changes. Based on individually set goals, experienced 
problems are identified and possible solutions will be put forward in a group brainstorm 
session. The participant will choose the most appropriate solution and creates and carries out 
an implementation plan. In this plan, the participant formulates the solution as a SMART 
(Specific, Measurable, Attainable, Realistic, Timely) goal and considers which steps should 
be taken to achieve this goal. Subsequently, the participants will be encouraged to identify 
barriers that may arise while trying to achieve their goals. Under guidance of the 
psychologist, activities will be defined which can be undertaken to prevent the occurrence or 
diminish the effect of these potentially threats (Proactive Coping).In following relapse 
prevention sessions, the implementation plan is evaluated and new (sub) problems are chosen 
to tackle. By linking Problem Solving Therapy to Proactive Coping and cognitive 
restructuring of (relapse) thoughts, we hope to have created a powerful intervention to 
provide participants skills to prevent and cope with relapse in their behaviour. 
Outcome assessment 
Outcome measurements (see below) are assessed at baseline (before start VLCD), and again 
at 4 months (after VLCD and 10 CPI sessions), 1 year, 1 ½ years and 2 years. 
Demographic variables are assessed at baseline by use of a self-administered questionnaire, 
which is checked during the intake interview with the investigator. 
All other secondary outcomes are assessed at baseline, after 4 months, 1 year, 1 ½ years and 
2 years, using self-administered questionnaires, except of the Session Rating Scale, which is 
filled in after every CPI session. 
Data are managed by use of the trial management system ‘EXPeRT Clinical’ of OmniComm, 
USA. 
Primary outcome 
The primary endpoint with respect to the efficacy of CPI is the differential course of weight 
(kg) between both study groups, measured at 8 weeks and at 2 years follow-up. Weight is 
measured to the nearest 0.1 kg, after removal of shoes using a Seca 888 compact digital flat 
scale. 
Secondary outcomes 
1. Anthropometric measurements: Height is measured to the nearest 0.5 cm without shoes 
using a Seca stadiometer. Body Mass Index is calculated as weight divided by height 
squared (BMI = weight (kg)/height (m)2). Waist circumference (cm) is measured at the 
level midway between the lowest rib margin and the aliac crest. Hip circumference is 
measured at the widest point over the buttocks. Both waist- and hip circumference are 
measured by the nearest 0,5 cm, using a tape-measure. Subsequently, waist-hip ratio 
(WHR) is calculated. 
2. Cardiovascular riskprofile by use of the UKPDS risk engine[49]: 
a. Systolic and diastolic blood pressure (mmHg) are measured twice in upright position, 
while the patient had rested for at least 5 minutes with an Omron M4-I Intelli-sense 
device. The second value will be used. 
b. Blood samples are taken to asses total cholesterol, LDL-cholesterol, HDL-cholesterol 
and triglycerides (mmol/l), measured on a Roche Modular P 800, reagents used from 
Roche, methods used from Roche are Cholesterol Chod-pap, HDL-c plus 3rd 
generation, LDL-c plus 2nd generation and Triglycerides GPO-PAP. 
 
3. Glycaemic control: 
a. HbA1c (mmol/mol), measured on a Menarini HA-8160, reversed-phase action 
exchange chromatography. 
b. HOMA-%S calculated by measuring fasting plasma glucose (mmol/l), (measured on a 
Roche Modular P 800, reagent used from Roche, method used from Roche is Glucose 
Hexokinase) and fasting insulin (mmol/l) 
c. Glucose lowering medication (insulin (IU/day) and antidiabetic agents (mg/day)) 
 
4. Psychological measurements 
a. Anxiety and depression are measured by the Hospital Anxiety and Depression Scale 
(HADS)[50,51]. The HADS consists of a 7-item Anxiety scale and a 7-item 
Depression Scale. The items are scored from 0 to 3 and the range of scores is 0 – 21. 
A score between 0 and 7 excludes depression/anxiety. A score of 8–10 indicates a 
possible depression/anxiety. A score of 11–21 is indicative of a probable 
depression/anxiety. 
b. Somatic symptoms are measured by the VOEG-13 (‘Vragenlijst Onderzoek Ervaren 
Gezondheid’),[52] a Dutch 13-item questionnaire used to measure the health of a 
population, often used in social science research. The items consist of somatic 
symptoms like headache, nervousness and lethargy and respondents indicate whether 
they have these symptoms or not. A higher score indicates more somatic symptoms 
and a worse perceived health. 
c. Fatigue is measured by the Checklist Individual Strength (CIS),[53] which quantifies 
subjective fatigue and related behavioral aspects. The CIS consists of 20 statements 
for which the respondent has to indicate on a 7-point scale to what extent the 
particular statement applies to him or her (1 = Yes, that is true; to 7 = No, that is not 
true). The statements refer to four fatigue aspects: (1) subjective fatigue (2) reduced 
motivation (3) reduced activity and (4) reduced concentration. For the CIS a cut-off 
point of >76 has been established [54]. People with a score above this cut-off point are 
at an increased risk of long-term sickness absence. 
d. Self-esteem is measured by the Rosenberg Self-Esteem Scale (RSE).[55] The RSE is a 
10-item questionnaire that measures global self-esteem. Items are scored on a 4-point 
scale. A higher score indicates a more positive self esteem. Scores below 21 indicate 
low self-esteem. 
e. Eating disorders are measured by the Eating Disorder Examination-Questionnaire 
(EDE-Q)[56], a 36 item questionnaire that measures concerns about shape, weight and 
eating, restraint and binge eating. Subscale scores for restraint and shape, weight and 
eating concern range between 0–6. A higher score indicates more severe eating 
psychopathology. Because binge eating cannot be measured reliably by the EDE-Q, 
we use a questionnaire composed by Werrij, et al.[28] for diagnosing binge eating 
disorder (BED), based on the DSM-IV criteria for BED. BED is diagnosed when 
respondents report eating binges twice a week or more. 
f. Session rating. How the participants value the sessions is measured by the Session 
Rating Scale (SRS).[57] The SRS is an ultra brief alliance measure designed 
specifically for every session clinical use. The SRS consists of four 10-cm visual 
analogue scales (relationship scale, goals and topic scale, approach or method scale, 
overall evaluation scale), with instructions to place a hash mark on a line (continuum) 
with negative responses depicted on the left and positive responses indicated on the 
right. Based on a total possible score of 40, any score lower than 36 overall, or 9 on 
any scale, could be a source of concern and therefore prudent to invite the client to 
comment. 
 
5. Lifestyle 
a. We developed a lifestyle questionnaire on diet history, smoking, drinking habits, drug 
use and hours sleep. (See additional file 1) 
b. Physical activity is measured using the SQUASH (Short Questionnaire to Assess 
Health Enhancing Physical Activity).[58] The SQUASH collects days per week, 
average time per day, and effort for physical activities such as commuting activities, 
leisure time and sport activities, household activities, and activities at work or school. 
Total minutes of activity are calculated for each question by multiplying frequency 
(days per week) by duration (minutes per day). Activity scores for separate questions 
are calculated by multiplying total minutes of activity by an intensity score (range 1–
9). The total activity score is calculated by taking the sum of the activity scores for the 
separate questions. 
 
6. Cost-effectiveness 
a. Quality of life is measured by the EuroQol (EQ-5D).[59,60] The EQ-5D is 5-item self 
report questionnaire on which participants report if they experience any problems in 
mobility, self-care, usual activities, pain and anxiety/depression. Each dimension has 3 
levels: no problems, some problems and severe problems. The scores on the three 
dimensions can be combined into one co called ‘utility’ score, which represents the 
societal value of quality of life. The utility score has a range from 1.00 (the value of 
health without health problems) till 0.00 (the value of health problems as bad a death). 
This societal value of quality of life is used as input for so called Quality Adjusted 
Life Years (QALY) analysis, as the societal perspective is the preferred perspective in 
health economics. The EuroQol instrument contains also the EQ-VAS, a vertical 
visual analogue scale with the anchors best imaginable health (score of 100) and worst 
imaginable health (score of 0). This EQ--VAS represents the patient’s perspective of 
quality of life. 
b. Costs are measured by the Trimbos/iMTA Questionnaire for Costs associated with 
Psychiatric Illness (TiC-P).[61] The TiC-P measures direct medical costs due to 
healthcare utilization during the past four weeks. Also, it registers the indirect non-
medical costs due to productivity loss during the past two weeks. 
 
Patient follow-up and compliance 
Follow-up measurements will take place combined with evaluation group meetings. 
For patients in both groups, follow-up visits to the physician, diabetes nurse and dietician are 
registered. 
A common limitation of weight loss studies is a selective loss to follow-up: higher drop-out 
rates occur among patients, who do not achieve their weight loss goals. We want to tackle 
this problem by use of incentives to keep all patients in the trial: motivating phone calls of the 
researcher, little gifts during the program, etc. 
Further more, we will perform a follow-up and analysis of the drop-outs after completion of 
the study and compare completers and drop-outs at base-line. For this purpose, the drop-outs 
will be interviewed by a medical student, who is not involved in the study. 
Compliance to the intervention is assessed by registration of the attendance to the CPI 
sessions: participants are considered non-compliant when they are absent on more then 8 
sessions. Since we expect that the treatment will be less effective when more then 8 sessions 
are missed, this non-compliant participants will be considered drop-outs. 
We have conducted a pilot study to improve our research protocol. We will not perform 
interim analyses and we will not define stopping rules, since the intervention has no serious 
side-effects. 
Data/results pilot study 
In order to test the protocol we conducted a pilot study, in which we included 13 patients to 
asses the study design and logistic pathways of the VLCD-period and the first 10 weeks of 
CPI. In this pilot study, we found that the protocol was feasible and that no major changes 
had to be done. The only change we made was in the lay-out of the questionnaires, making 
them better understandable to our participants. Results of this pilot study (baseline and T=4 
months) are shown below (Table 4 and 5). 
Table 4 baseline characteristics pilot group 
 Baseline (n=13)  
Sex (%) Males 25% 
Females 75% 
Age (y)  49.5 
Insulin dependant (%) Insulin dependant 75% 
Non-insulin dependant (OAD) 25% 
Table 5 Outcome measurements pilot group 
 Baseline (n=13) T1 = 4 months (n=13) 95%CI 
Weight (kg) 114.8 106.0*** [5.2-12.4] 
Waist circumference (cm) 121.4 113.7** [3.2-12.2] 
Systolic BP (mmHg) 144.6 127.9* [1.1-32.2] 
Diastolic BP (mmHg) 86.1 78.0 [−0.4-16.7] 
Total cholesterol (mmol/l) 5.0 4.5 [−0.2-1.3] 
HDL cholesterol (mmol/l) 1.7 1.3 [−0.3-1.3] 
LDL cholesterol (mmol/l) 2.6 2.5 [−0.3-0.5] 
Triglycerides (mmol/l) 3.6 2.6 [−1.1-3.0] 
HbA1c (mmol/mol) 66.3 66.6 [−9.8-9.1] 
Insulin (IU) 82.3 32.3* [7.3-94.7] 
Depression score (HAD) 
>8 = (sub)clinical 
5.7 4.6 [−1.5-3.7] 
Paired samples T-test *p<0.05 **p<0.01 ***p<0.001 
Statistical analyses 
All analyses will be conducted according to the intention-to-treat as well as the on-treatment 
principle. We consider participants on-treatment when they miss less then 8 sessions CPI. 
At baseline, comparability between the control- and intervention group will be assessed to 
test the success of the randomization. As measures of central tendency for numerical data we 
will use the mean (in case of normal distribution) and median values (in case of non-normal 
distribution), with respectively the standard deviation and interquartile range as measures of 
dispersion. 
Mixed modelling, also known as random effect modelling, multilevel or hierarchical linear 
regression analyses will be applied for longitudinal analyses of the data. Mixed modelling can 
efficiently handle data with missing and unbalanced time-points. It corrects for bias when 
absence of data is dependent on characteristics that are present in the models (missing at 
random, MAR) [62]. There will be two levels in the models. The patients constitute the upper 
level, their repeated measures the lower level. First, for each outcome variable a saturated 
model will be postulated, with the primary or secondary outcomes as dependent variables. 
The saturated models will include treatment group, time, quadratic time, logarithm of time 
and all treatment-time interactions as fixed effects. The deviance statistic [63] using restricted 
maximum likelihood [64] will be applied to determine the covariance structure. Next, using 
Wald tests, the saturated models will be reduced by eliminating insignificant fixed effects. 
The significance of the difference between the saturated models and the parsimonious final 
models will be determined with the deviance statistics using ordinary likelihood. 
Discussion 
To our knowledge, this trial is the first randomized controlled trial to test the effects of an 
integrated multi-model cognitive group therapy in the battle against weight regain after a 
successful weight loss intervention (VLCD) in patients with type 2 diabetes. Weight regain is 
common in the obese population in general, but even more pronounced in the diabetes type 2 
population, and with more devastating effects on their health outcomes. The strength of this 
study is the combined psychological intervention (CPI) of cognitive restructuring, problem 
solving treatment and proactive coping, which will provide powerful tools to the participants 
for maintaining behavioral change and improving health outcomes. We expect that adding 
CPI to a VLCD will be effective in maintaining weight loss, improving lifestyle and, as a 
result, leading to improved glycaemic control and a reduction of cardiovascular risk. 
We expect that a number of factors may influence the treatment effect, therefore we will also 
examine potential determinants of weight maintenance, such as depression, anxiety, self-
esteem, fatigue, somatic symptoms, eating disorders and lifestyle. Apart from being 
predictive for the success of the intervention, these factors may be changed by the treatment 
itself and therefore will be followed over time as secondary outcome measurements. 
It is expected that if the intervention is successful, it will also be cost effective since the costs 
of group counselling are relatively low and the expected reduction of medication, prevention 
or delay of complications and a reduction of hospital admissions are considered major cost 
savings. If the therapy is indeed effective, a formal cost effectiveness analysis will be 
performed. 
Few studies have implemented interventions to sustain weight loss for longer then 18 months. 
In this study, we opt for a follow-up period of 2 years, enabling predictions on long-term 
behavioral change and weight maintenance. During the follow-up period, participants will 
have relapse-prevention group meetings with increasing intervals to stabilize behaviour. It is 
known that the effect of an intervention reduces when the contact with the therapist stops, and 
one can therefore expect that the participants experience a relapse in their behaviour after the 
follow-up period. The last session op CPI will be at 1,5 years after randomization, leaving the 
participants 6 months ‘to themselves’. Obviously, our patients remain under supervision of 
the healthcare team after completion of the study and will be encouraged to continue their 
good habits. Nevertheless, after 5 years, we will try to repeat the assessment of the main 
outcome variables to determine the long-term effect. 
Limitations 
This trial is explanatory in design in relation to the measures of process but pragmatic in 
terms of the comparison with usual care rather than a specified alternative group. We chose 
this design to enable analysis of an additional intervention on top of usual care in a 
population already receiving multiple interventions. The pragmatic approach and planned 
economic analysis aim to facilitate implementation of the intervention when successful, but 
this design does not identify the optimal psychological therapy. 
If the intervention is successful, it cannot be ascertained which of the 3 therapies involved 
determined the success. However, each of the treatments has been studied separately and is 
more or less proven effective in achieving weight reduction and maintenance.[20,26,28-
32,34-36,40] We expect that a diet with a combination of several forms of cognitive 
behaviour therapy together will have a greater impact than the individual factors. 
Clearly the assumption is that the overlap of effects of the different types of interventions is 
negligible. This is not necessarily true. Hence, the present study is designed to study the 
effect of a combination therapy, but cannot identify the optimal combination of interventions. 
Another limitation is the comparison to usual care only. One could argue that the participants 
in the intervention group may benefit from the attention they get, and not necessarily from the 
CPI. In our study design, it is impossible to distinguish between the effect of attention and the 
effect of the intervention itself. Our choice to compare our intervention on top of usual care 
with usual care only, is based on the fact that this kind of comparative effectiveness design 
has more clinical relevance. Such design is a necessary condition for a cost effectiveness 
analysis, as cost effectiveness is measured in relation to the dominant alternative treatment 
strategy. Moreover, the individual interventions have been shown effective in comparison 
with other psychological interventions, exercise or placebo as a control.[27,35,40,65] 
We are aware of the fact that our population is not generalizable to the entire group of 
overweight patients with type 2 diabetes. 
One can speculate that patients, who agree to participate in the study and are able to achieve a 
5% weight reduction in 8 weeks, are expected to be more motivated then patients, who refuse 
to participate or who fail to lose sufficient weight. Randomization will distribute this 
selection bias equally to the CPI and the control group. Nonetheless, our findings will solely 
be applicable to patients, who are motivated to reduce their body weight. 
Our hospital is a tertiary referral centre and as a result the patients often have end stage 
disease with multiple complications. Due to this selection, motivation, compliance and 
treatment outcome are expected to be low, potentially resulting in underestimation of the 
effect. However, GP’s will also be able to refer their eligible patients directly to the trial. 
Those patients often have less severe disease and complications. 
Insufficient command of the Dutch language is an exclusion criterion of this investigation, 
because the cognitive training is given in Dutch and the workbook and homework 
assignments must be understood and carried out in Dutch as well. In this way, a part of the 
immigrant population is excluded and the study population will not reflect the entire diabetic 
population of the Erasmus MC. 
We will use incentives (motivating phone calls, little booklets etc.) to minimize drop-out. 
This effect will be the same for the control group and the intervention group, not affecting the 
results. However, it will have an effect on the generalizability of the study because the less 
motivated participants are more likely to remain in the study where they would normally 
drop-out. 
We are aware of the impact, especially on the control group, of the large measurement burden 
due to all the psychological questionnaires. We will discuss this with the participants 
beforehand and expect that they find 5 times 30 minutes of completing questionnaires is 
acceptable in the light of the weight loss intervention they will receive. 
Future implementation 
If this intervention proves to be effective and cost-effective, we will promote implementation 
into diabetes care. 
In the present study, we use a VLCD because it leads to quick and substantial weight loss, but 
off course the multi-model cognitive therapy can be combined with any weight loss 
intervention (i.e. low calorie diet, low carbohydrate diet, exercise), to sustain the effect. 
The study will start in 2010 and the inclusion of patients will take approximately 3 years. 
After the follow-up period of 2 years, we expect the results to become available in 2015. 
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